NCT03154515

Efficacy and Safety Study of Ingavirin® 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections in Adults

Randomised Double Blind Placebo Controlled Multicenter Study for Evaluation of Clinical Efficacy and Safety of Ingavirin 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections in Adults.

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 445 (actual)
• Sponsor: Valenta Pharm JSC · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether Ingavirin® 90 mg once daily is effective and safe for the treatment of influenza and other laboratory confirmed acute respiratory viral infections in the course of standard therapy in patients 18-60 years old.

Detailed description

Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Ingavirin in the Treatment of Influenza and Other Acute Viral Respiratory Infection. Study treatment was 5 days followed by 2 ± 1 days of follow up period. Thus, study participation was 7 ± 1 days (8 days max).

Conditions

• Common Cold
• Influenza, Human
• Acute Respiratory Infection

Interventions

Type	Name	Description
DRUG	Ingavirin
DRUG	Placebo

Timeline

• Start date: 2010-01-01
• Primary completion: 2014-04-01
• Completion: 2014-10-01
• First posted: 2017-05-16
• Last updated: 2017-05-16

Locations

9 sites across 1 country: Russia